Share-based Payment Arrangement, Expense of Aptevo Therapeutics Inc. from 30 Sep 2015 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aptevo Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2015 to 31 Mar 2025.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $180,000, a 75% decline year-over-year.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $530,000, a 73% decline year-over-year.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,069,000, a 51% decline from 2023.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,193,000, a 22% increase from 2022.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,802,000, a 9.7% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aptevo Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $530,000 $180,000 -$539,000 -75% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,069,000 $72,000 -$430,000 -120% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
Q3 2024 $1,499,000 $149,000 -$306,000 -67% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $1,805,000 $273,000 -$192,000 -41% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $1,997,000 $719,000 -$196,000 -21% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $2,193,000 $358,000 $0 0% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
Q3 2023 $2,193,000 $455,000 +$96,000 +27% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $2,097,000 $465,000 -$19,000 -3.9% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $2,116,000 $915,000 +$314,000 +52% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $1,802,000 $358,000 +$180,000 +101% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $1,622,000 $359,000 +$40,000 +13% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $1,582,000 $484,000 -$88,000 -15% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,670,000 $601,000 +$27,000 +4.7% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $1,643,000 $178,000 -$20,000 -10% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $1,663,000 $319,000 -$24,000 -7% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,687,000 $572,000 +$271,000 +90% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,416,000 $574,000 +$161,000 +39% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,255,000 $198,000 -$71,000 -26% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $1,326,000 $343,000 +$9,000 +2.7% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,317,000 $301,000 -$100,000 -25% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,417,000 $413,000 -$181,000 -30% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $1,598,000 $269,000 -$224,000 -45% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q3 2019 $1,822,000 $334,000 -$147,000 -31% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $1,969,000 $401,000 -$48,000 -11% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $2,017,000 $594,000 -$123,000 -17% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $2,140,000 $493,000 -$573,000 -54% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2020 2019 FY
Q3 2018 $2,713,000 $481,000 -$559,000 -54% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,272,000 $449,000 -$651,000 -59% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $3,923,000 $717,000 -$961,000 -57% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $4,884,000 $1,066,000 +$1,683,000 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q3 2017 $3,201,000 $1,040,000 -$293,000 -22% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $3,494,000 $1,100,000 +$700,000 +175% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $2,794,000 $1,678,000 -$1,015,000 -38% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $3,809,000 $617,000 01 Oct 2016 31 Dec 2016 10-K 13 Mar 2018 2017 FY
Q3 2016 $1,333,000 +$1,052,000 +374% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 $400,000 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $2,693,000 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017 2017 Q1
Q3 2015 $281,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3

Aptevo Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,069,000 -$1,124,000 -51% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
2023 $2,193,000 +$391,000 +22% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
2022 $1,802,000 +$159,000 +9.7% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $1,643,000 +$388,000 +31% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $1,255,000 -$343,000 -21% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $1,598,000 -$542,000 -25% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
2018 $2,140,000 -$2,744,000 -56% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2020 2019 FY
2017 $4,884,000 +$1,075,000 +28% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $3,809,000 +$2,702,000 +244% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2018 2017 FY
2015 $1,107,000 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.